Estrogen receptor (ER) is highly expressed in 70%-80% of breast cancers and plays a
central role in prognosis and treatment selection for patients with breast cancer. The gold …

Breast cancer is one of the most common malignancies in women, with high morbidity and
mortality rates. In breast cancer, the use of novel radiopharmaceuticals in nuclear medicine …

PET imaging with 16α-18F-fluoro-17β-fluoroestradiol (18F-FES), a radiolabeled form of
estradiol, allows whole-body, noninvasive evaluation of estrogen receptor (ER). 18F-FES is …

PURPOSE Determining the estrogen receptor (ER) status is essential in metastatic breast
cancer (MBC) management. Whole-body ER imaging with 16α-[18F] fluoro-17β-estradiol …

Simple Summary About 10–20% of breast cancer patients have a heterogeneous estrogen
receptor expression. The diagnosis and treatment strategy remains controversial in these …

ER, PgR and HER‐2 status are the cornerstones of choosing systemic therapy for breast
cancer, but can change during the disease course. Guidelines recommended the biopsy of …

Breast Cancer (BC) is the most common cancer worldwide and, despite the advancements
made toward early diagnosis and novel treatments, there is an urgent need to reduce its …

Estrogen Receptor-Targeted and Progesterone Receptor-Targeted PET for Patients with Breast
Cancer - PET Clinics Skip to Main Content Advertisement PET Clinics Log in Register Log in …

The clinical value of 16α-18 F-fluoro-17 β-estradiol (18 F-FES) PET in breast cancer has
been widely investigated because it can visualize estrogen receptor–expressing lesions …

Purpose This expert review describes the development and foundational studies of [18F]
fluoroestradiol (18F-FES) in the setting of imaging estrogen receptor (ER)-positive breast …